Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

European Journal of Cancer

Volumn 48, Issue 10, 2012, Pages 1466-1475

  Bokemeyer, Carsten ^a   Cutsem, Eric Van ^b   Rougier, Philippe ^c   Ciardiello, Fortunato ^d   Heeger, Steffen ^e   Schlichting, Michael ^e   Celik, Ilhan ^e   Köhne, Claus Henning ^f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e MERCK KGAA   (Germany)

^f KLINIKUM OLDENBURG   (Germany)

Author keywords

BRAF; Cetuximab; Colorectal cancer; KRAS

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84862026304     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.057     Document Type: Article

References (23)

1. I.A. Lea, M.A. Jackson, and X. Li Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns Carcinogenesis 28 2007 1851 1858
2. N. Normanno, S. Tejpar, and F. Morgillo Implications for KRAS status and EGFR-targeted therapies in metastatic CRC Nat Rev Clin Oncol 6 2009 519 527
3. W. De Roock, H. Piessevaux, and J. De Schutter KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 2008 508 515
4. F. Di Fiore, F. Blanchard, and F. Charbonnier Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 2007 1166 1169
5. A. Lievre, J.B. Bachet, and V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379
6. A. Lievre, J.B. Bachet, and D. Le Corre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
7. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
8. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
9. E. Van Cutsem, C.H. Kohne, and I. Lang Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
10. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
11. H. Ji, Z. Wang, and S.A. Perera Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models Cancer Res 67 2007 4933 4939
12. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
13. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
14. F. Loupakis, A. Ruzzo, and C. Cremolini KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 2009 715 721
15. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
16. I. Zlobec, M.P. Bihl, H. Schwarb, L. Terracciano, and A. Lugli Clinico-pathological and protein characterization of BRAF and K-RAS mutated colorectal cancer and implications for prognosis Int J Cancer 127 2009 367 380
17. G.H. Lyman, and N.M. Kuderer The strengths and limitations of meta-analyses based on aggregate data BMC Med Res Methodol 5 2005 14
18. M. Egger, and G.D. Smith Meta-Analysis. Potentials and promise BMJ 315 1997 1371 1374
19. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
20. C.J. Punt Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer? Ann Oncol 16 2005 845 846
21. J. Tol, J.R. Dijkstra, and M. Klomp Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab Eur J Cancer 46 2010 1997 2009
22. S.D. Richman, M.T. Seymour, and P. Chambers KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 2009 5931 5937
23. A.D. Roth, S. Tejpar, and M. Delorenzi Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474